The report describes the company's ESG performance during 2022, including the release of its first inhalable COVID-19 vaccine Convidecia Air®, approval for emergency use by the World Health Organization, and the launch of its first tetravalent meningococcal conjugate vaccine Menhycia®. The report covers areas such as corporate governance, risk management, product quality, innovation, social responsibility, and environmental protection.
Issuing Company Cansino Biologics Inc.
Report Type Sustainability Report
Report Language EN
Report Filesize 15.28 MB
No. of Pages 61 pages
Reporting periodJanuary 1, 2022-December 31, 2022
Report Edition4
Assurance Provider Unknown
Reporting Standards GRI; Environmental Information Disclosure Guidelines for Liste...
Materiality Assessmenttrue